This infographic summarizes the findings of a systematic review and meta-analysis of randomized controlled trials comparing selective cannabinoids with conventional pharmacologic and/or physical therapy in patients with chronic neuropathic pain. The results of the analysis suggest a mild reduction in numerical pain scores with improvements in quality of life and sleep. Due to a high degree of variability in quality of reporting, etiology of neuropathic pain, and type and dose of cannabinoids, more rigorous randomized controlled trials are needed to further define the role of cannabinoids in neuropathic pain.
CI indicates confidence interval; RCT, randomized controlled trial; THC, tetrahydrocannabinol.
1. Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017;125:1638–1652.